UA100232C2 - Кристалічні форми інгібітора glyt1 - Google Patents
Кристалічні форми інгібітора glyt1Info
- Publication number
- UA100232C2 UA100232C2 UAA200907731A UAA200907731A UA100232C2 UA 100232 C2 UA100232 C2 UA 100232C2 UA A200907731 A UAA200907731 A UA A200907731A UA A200907731 A UAA200907731 A UA A200907731A UA 100232 C2 UA100232 C2 UA 100232C2
- Authority
- UA
- Ukraine
- Prior art keywords
- crystalline forms
- glyt1
- preparation
- present
- methanone
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- YUUGYIUSCYNSQR-LBPRGKRZSA-N [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-LBPRGKRZSA-N 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269 | 2006-12-28 | ||
| PCT/EP2007/064104 WO2008080821A1 (en) | 2006-12-28 | 2007-12-18 | Crystalline forms glyt1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA100232C2 true UA100232C2 (uk) | 2012-12-10 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200907731A UA100232C2 (uk) | 2006-12-28 | 2007-12-18 | Кристалічні форми інгібітора glyt1 |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20080214561A1 (OSRAM) |
| EP (1) | EP2114405B1 (OSRAM) |
| JP (1) | JP4799666B2 (OSRAM) |
| KR (1) | KR101130146B1 (OSRAM) |
| CN (1) | CN101573114A (OSRAM) |
| AR (1) | AR064545A1 (OSRAM) |
| AU (1) | AU2007341356B2 (OSRAM) |
| BR (1) | BRPI0720829B8 (OSRAM) |
| CA (1) | CA2673667A1 (OSRAM) |
| CL (1) | CL2007003830A1 (OSRAM) |
| CO (1) | CO6190613A2 (OSRAM) |
| CR (1) | CR10846A (OSRAM) |
| CY (1) | CY1116350T1 (OSRAM) |
| DK (1) | DK2114405T3 (OSRAM) |
| EC (1) | ECSP099471A (OSRAM) |
| ES (1) | ES2535040T3 (OSRAM) |
| HR (1) | HRP20150573T1 (OSRAM) |
| HU (1) | HUE025032T2 (OSRAM) |
| MA (1) | MA31029B1 (OSRAM) |
| MX (1) | MX2009006859A (OSRAM) |
| MY (1) | MY188367A (OSRAM) |
| NO (1) | NO342150B1 (OSRAM) |
| NZ (1) | NZ577502A (OSRAM) |
| PE (1) | PE20081556A1 (OSRAM) |
| PL (1) | PL2114405T3 (OSRAM) |
| PT (1) | PT2114405E (OSRAM) |
| RS (1) | RS53910B1 (OSRAM) |
| RU (1) | RU2463295C2 (OSRAM) |
| SI (1) | SI2114405T1 (OSRAM) |
| TW (1) | TWI388552B (OSRAM) |
| UA (1) | UA100232C2 (OSRAM) |
| WO (1) | WO2008080821A1 (OSRAM) |
| ZA (1) | ZA200904423B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101573114A (zh) | 2006-12-28 | 2009-11-04 | 弗·哈夫曼-拉罗切有限公司 | 结晶形式glyt1 |
| WO2010099323A1 (en) * | 2009-02-26 | 2010-09-02 | Thar Pharmaceuticals, Inc. | Crystalization of pharmaceutical compounds |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| EA201401312A1 (ru) * | 2012-05-25 | 2015-09-30 | Басф Се | КРИСТАЛЛИЧЕСКАЯ ФОРМА В 1,5-ДИМЕТИЛ-6-ТИОКСО-3-(2,2,7-ТРИФТОР-3-ОКСО-4-(ПРОП-2-ИНИЛ)-3,4-ДИГИДРО-2Н-БЕНЗО[b][1,4]ОКСАЗИН-6-ИЛ)-1,3,5-ТРИАЗИНАН-2,4-ДИОНА |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| CA3166938A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| WO2022014396A1 (ja) * | 2020-07-13 | 2022-01-20 | 日本碍子株式会社 | 精製方法 |
| JP2024518091A (ja) * | 2021-05-14 | 2024-04-24 | ディスク・メディシン・インコーポレイテッド | グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
| JP2024520391A (ja) * | 2021-05-27 | 2024-05-24 | ディスク・メディシン・インコーポレイテッド | ビトペルチンの固体形態を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| RS53252B (sr) * | 2003-08-11 | 2014-08-29 | F.Hoffmann-La Roche Ag. | Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| CN101573114A (zh) | 2006-12-28 | 2009-11-04 | 弗·哈夫曼-拉罗切有限公司 | 结晶形式glyt1 |
-
2007
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA100232C2 (uk) | Кристалічні форми інгібітора glyt1 | |
| MXPA06002727A (es) | Derivados de 1-(2-amino-benzol)-piperazina como inhibidores de la captacion de glicina para el tratamiento de psicosis. | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| MY145356A (en) | Piperzine with or-substitution for glyt1 | |
| MX2009011830A (es) | Compuestos amino-heterociclicos. | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| CU20110106A7 (es) | Nuevos compuestos 578 | |
| TW200505907A (en) | Piperidine-benzenesulfonamide derivatives | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| NZ593279A (en) | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors | |
| IL198926A0 (en) | Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition | |
| TW200633957A (en) | Compounds | |
| MXPA05004273A (es) | Derivados de fenilalquil y piridilalquil piperazina. | |
| GB0428232D0 (en) | Compounds | |
| TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| TW200633956A (en) | Compounds | |
| WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| EA200870492A1 (ru) | N-оксиды производных пиридилметилпиперазина и - пиперидина | |
| WO2005097114A3 (en) | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | |
| MX2010008239A (es) | 2-aminoquinolinas. | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
| TH92210B (th) | รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone) | |
| IN2009CN03566A (OSRAM) | ||
| WO2011015646A3 (en) | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders | |
| TH107358A (th) | รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone) |